The Pharming Group NV is set to receive $15 million upfront from Santarus Inc as part of a commercialisation deal for North America for Rhucin, its recombinant protein for hereditary angioedema. Pharming is planning an FDA filing soon.
The Pharming Group NV is set to receive $15 million upfront from Santarus Inc as part of a commercialisation deal for North America for Rhucin, its recombinant protein for hereditary angioedema. Pharming is planning an FDA filing soon.